Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 5/20 | 0.38 |
| ▸ | BCL2L2 | Q92843 | 5/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459640 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRBCL2BCL2L2GCK | |
| SCHEMBL8515260 | 0.76 | LMNA (0.43) | GCKMCL1NTSR1MMP1MMP3 | |
| SCHEMBL21459362 | 0.76 | BCL2 (0.47) | ALDH1A1BCL2BCL2L2MCL1NTSR1 | |
| SCHEMBL21459361 | 0.76 | BCL2 (0.47) | ALDH1A1BCL2BCL2L2MCL1NTSR1 | |
| SCHEMBL21459812 | 0.75 | GCK (0.45) | ALDH1A1BCL2BCL2L2GCKMCL1 | |
| SCHEMBL21484480 | 0.75 | GCK (0.45) | ALDH1A1BCL2BCL2L2GCKMCL1 | |
| SCHEMBL21459810 | 0.75 | GCK (0.45) | ALDH1A1BCL2BCL2L2GCKMCL1 | |
| SCHEMBL28511063 | 0.74 | MCL1 (0.47) | BCL2BCL2L2GCKMCL1SMN1; SMN2 | |
| SCHEMBL1106466 | 0.74 | NFATC1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL21852156 | 0.74 | ALDH1A1 (0.66) | ALDH1A1TSHRBCL2BCL2L2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | ALDH1A1 1396/4885TSHR 1169/4885BCL2 4496/4885 |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | ALDH1A1 1361/4885TSHR 1185/4885BCL2 4069/4885 |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | ALDH1A1 1361/4885TSHR 1185/4885BCL2 4069/4885 |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | ALDH1A1 1361/4885TSHR 1185/4885BCL2 4069/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | ALDH1A1 1457/4885TSHR 959/4885BCL2 4186/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | ALDH1A1 1361/4885TSHR 1185/4885BCL2 4069/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | ALDH1A1 1396/4885TSHR 1169/4885BCL2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.